MX2011012201A - Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico. - Google Patents

Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.

Info

Publication number
MX2011012201A
MX2011012201A MX2011012201A MX2011012201A MX2011012201A MX 2011012201 A MX2011012201 A MX 2011012201A MX 2011012201 A MX2011012201 A MX 2011012201A MX 2011012201 A MX2011012201 A MX 2011012201A MX 2011012201 A MX2011012201 A MX 2011012201A
Authority
MX
Mexico
Prior art keywords
combination
pbospboinositkle
ksï
treatment
antidiabetic compound
Prior art date
Application number
MX2011012201A
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Sauveur-Michel Maira
Jose Baselga
Serena Di Cosimo
Wolfgang Hackl
Michelangelo Russillo
Violeta Serra Elizalde
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011012201A publication Critical patent/MX2011012201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación farmacéutica que comprende: (a) un compuesto inhibidor de la cinasa de fosfoinositida-3, y (b) un compuesto potenciador de la sensibilidad a la insulina, para el tratamiento de una enfermedad proliferativa, en especial de una enfermedad de un tumor sólido; una composición farmacéutica, la cual comprende dicha combinación; el uso de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; un paquete o producto comercial que comprende esta combinación como una preparación combinada para su uso simultáneo, separado, o en secuencia; y un método para el tratamiento de un animal de sangre caliente, en especial de un ser humano.
MX2011012201A 2009-05-15 2010-05-12 Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico. MX2011012201A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160440 2009-05-15
PCT/EP2010/056538 WO2010130779A2 (en) 2009-05-15 2010-05-12 COMBINATION OF A PBOSPBOINOSITKLE 3-KSπASE INHIBITOR AND AN ANTIDIABETIC COMPOUND

Publications (1)

Publication Number Publication Date
MX2011012201A true MX2011012201A (es) 2011-12-08

Family

ID=40983590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012201A MX2011012201A (es) 2009-05-15 2010-05-12 Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.

Country Status (11)

Country Link
US (1) US20120059005A1 (es)
EP (1) EP2429516A2 (es)
JP (1) JP2012526772A (es)
KR (1) KR20120096869A (es)
CN (1) CN102958518A (es)
AU (1) AU2010247397B2 (es)
BR (1) BRPI1010979A2 (es)
CA (1) CA2760179A1 (es)
MX (1) MX2011012201A (es)
RU (1) RU2011150619A (es)
WO (1) WO2010130779A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
ES2699951T3 (es) * 2010-10-01 2019-02-13 Novartis Ag Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina, un inhibidor PIK3
US10195219B2 (en) * 2013-04-12 2019-02-05 Ned Biosystems, Inc. Cancer therapy
WO2018027084A2 (en) * 2016-08-03 2018-02-08 Remd Biotherapeutics, Inc. Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
EP3801069A4 (en) * 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
JP2021532139A (ja) * 2018-07-23 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤であるｇｄｃ−００７７による癌の治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176425A1 (en) * 2003-01-24 2004-09-09 Washburn William N. Cycloalkyl containing anilide ligands for the thyroid receptor
JP5371426B2 (ja) * 2004-07-09 2013-12-18 プロルックス ファーマシューティカルズ コープ． ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
US7714005B2 (en) * 2004-12-22 2010-05-11 The Ohio State University Research Foundation Small molecule Bcl-xL/Bcl-2 binding inhibitors
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008021210A2 (en) * 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EP2120909A2 (en) * 2006-12-15 2009-11-25 Ordway Research Institute Treatments of therapy-resistant diseases comprising drug combinations
JP2011506455A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
MX2011000440A (es) * 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.

Also Published As

Publication number Publication date
RU2011150619A (ru) 2013-06-20
CN102958518A (zh) 2013-03-06
EP2429516A2 (en) 2012-03-21
US20120059005A1 (en) 2012-03-08
CA2760179A1 (en) 2010-11-18
JP2012526772A (ja) 2012-11-01
BRPI1010979A2 (pt) 2018-03-06
WO2010130779A3 (en) 2013-03-28
WO2010130779A2 (en) 2010-11-18
AU2010247397B2 (en) 2012-07-12
KR20120096869A (ko) 2012-08-31
AU2010247397A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
MX336723B (es) Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
MX2014005927A (es) Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2.
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
WO2005074989A3 (en) Combination of a dna topoisomerase inhibitor and an iap inhibitor
MX2012005365A (es) Formulaciones de tableta de liberacion inmediata.
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
UA106634C2 (uk) Тверда фармацевтична дозована форма
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
MX2011012201A (es) Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.
IN2012DN02139A (es)
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
WO2010147440A3 (ko) 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
PL2471781T3 (pl) Związki etery benzylowo-aralkilowe, sposób ich wytwarzania, półprodukty, zastosowanie wymienionych związków, sposoby leczenia i/lub zapobiegania, kompozycja farmaceutyczna i lek je zawierający
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2010081731A3 (en) Derivatives of syringolin a
WO2010099510A3 (en) Amino acid-based compounds, their methods of use, and methods of screening
MX362533B (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.
WO2010093615A3 (en) Compounds, their syntheses, compositions, and methods to treat cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal